Krystal Biotech (KRYS) Gets a Buy Rating from William Blair

By Jason Carr

In a report released today, Raju Prasad from William Blair maintained a Buy rating on Krystal Biotech (KRYSResearch Report). The company’s shares closed last Monday at $45.00.

According to, Prasad is a 5-star analyst with an average return of 11.2% and a 52.7% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.

Currently, the analyst consensus on Krystal Biotech is a Strong Buy with an average price target of $81.00, representing a 78.5% upside. In a report issued on April 30, H.C. Wainwright also reiterated a Buy rating on the stock with a $68.00 price target.

See today’s analyst top recommended stocks >>

Based on Krystal Biotech’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $5.36 million. In comparison, last year the company had a GAAP net loss of $3.71 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.